Lenvima (Lenvatinib)

Lenvatinib inhibits multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT. Blocking these receptors reduces new blood‑vessel formation and interferes with signalling pathways that promote tumour cell proliferation, thereby slowing disease progression.

The appropriate dose of Lenvima is determined individually by the prescribing oncologist based on the specific cancer type, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Lenvima is classified as contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. Breastfeeding is not recommended, as the drug may be excreted in milk.

To order Lenvima, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenvima uniquely targets a broad spectrum of kinases, including VEGFR, FGFR, PDGFRα, RET and KIT, offering a wider anti‑angiogenic profile than some single‑target TKIs. This multi‑target approach can be advantageous in tumours that rely on several growth‑factor pathways, but the safety profile and drug‑interaction potential also differ and must be considered.

Lenvima tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Protect the medication from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Lenvima is taken orally as a tablet, usually once daily on an empty stomach (at least one hour before or two hours after a meal). The tablet should be swallowed whole with water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include severe hypertension, liver toxicity, cardiac dysfunction (including reduced ejection fraction), gastrointestinal perforation, and life‑threatening bleeding or thromboembolic events. Patients should be monitored closely for these events, and any concerning symptoms should be reported to a clinician immediately.

Lenvima is contraindicated in patients with known hypersensitivity to lenvatinib or any of its excipients. It should be avoided in individuals who are pregnant, breastfeeding, or have uncontrolled hypertension, severe hepatic impairment, or significant cardiac disease without appropriate medical supervision.